
Human MAGE B2 231-240, GVYDGEEHSV
Description
About Human MAGE B2 231-240, GVYDGEEHSV
The Human Melanoma-associated antigen (MAGE) B2 Peptide (IEDB: 23214) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Melanoma-associated antigen (MAGE) Peptide, H-GVYDGEEHSV-OH (Uniprot: O15479 aa: 231-240) from JPT is produced under strict quality control and quality management.
Human MAGE B2 231-240, GVYDGEEHSV - Specifications
- Peptide sequence: H-GVYDGEEHSV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Melanoma, Hepatocellular carcinoma
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human MAGE B2 231-240, GVYDGEEHSV
References:
Read References with JPT’s Antigen Peptides
Human MAGE B2 231-240, GVYDGEEHSV has been described in:
Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF., Front Immunol, 2020 (PMID: 32582212)
Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients., Oncoimmunology, 2022 (PMID: 36211805)
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides., J Immunol, 1995 (PMID: 7538538)
Documentation
Documentation for Human MAGE B2 231-240, GVYDGEEHSV
Properties
Properties of Human MAGE B2 231-240, GVYDGEEHSV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Hepatocellular carcinoma, Melanoma |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Melanoma-associated antigen (MAGE) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human MAGE B2 231-240, GVYDGEEHSV
Information | Values |
---|---|
Sequence: | H-GVYDGEEHSV-OH |
Specifications: | 10mer peptide as TFA salt |